Anti-PD-L1
Anti-PD-L1 agents are monoclonal antibodies that block CD274 molecule from engaging its receptor Programmed cell death 1 (PD-1), and from engaging B7-1 (CD80).
Anti-PD-L1 agents are monoclonal antibodies that block CD274 molecule from engaging its receptor Programmed cell death 1 (PD-1), and from engaging B7-1 (CD80). Tumors and myeloid cells in the tumor microenvironment exploit that ligation to switch off cytotoxic T cells; blocking it restores their activation, proliferation, and killing. Approved agents include atezolizumab, durvalumab, and avelumab. They are used in non-small cell lung cancer, small cell lung cancer, urothelial and bladder cancer, hepatocellular and biliary tract cancer, and Merkel cell carcinoma, typically combined with chemotherapy or, in hepatocellular carcinoma, with antiangiogenic therapy.
Blocking the ligand rather than the receptor is the pair's practical difference: melanoma, where the class is not a standard option, is treated with anti-PD-1 and anti-CTLA-4 agents instead. PD-L1 expression by immunohistochemistry, scored as tumor proportion score or combined positive score, is the routine companion biomarker, but it predicts response imperfectly — expression is dynamic, focal, and driven by interferon signaling — so tumor mutational burden and mismatch repair status are used alongside it. Most patients still do not respond, which is why current work pairs PD-L1 blockade with a second, mechanistically distinct intervention.
Where the papers sit
20 papers from the last 6 months study Anti-PD-L1 directly · updated from PubMed 5 Nov 2026
Study type 0 clinical trials · 2 human data · 16 preclinical · 2 unclassified
Themes 3 themes · 1 new direction
-
Metabolic Tumor Immunotherapy
Combination therapy is shifting toward remodeling tumor metabolism and immunity alongside checkpoint blockade. Lactate, hypoxia, lactylation, lipid metabolism and CD49b-driven suppression recur as barriers to CD8-positive T-cell activity. Chemotherapy, oncolytic viruses, probiotics and chemophotodynamic nanoparticles are being paired with anti-PD-L1 to improve activation and tumor control. Evidence remains largely preclinical, leaving the best metabolic targets and translational strategy open.
7 papers · 35%
-
PD-L1 Resistance and Targeting
PD-L1 therapy is expanding beyond antibody blockade toward restoring sensitivity and engaging complementary pathways. Ubiquitination control through β-TrCP and USP5, with downstream FOXM1 and Nectin2, recurs as a resistance mechanism, while cuproptosis and stem-like lymphoid niches offer alternative routes to immune activation. Small-molecule inhibitors and PD-L1/VEGF bispecific antibodies broaden the therapeutic designs. Disease-specific immune landscapes remain important for predicting response.
7 papers · 35%
-
Nanomedicine for Tumor Immunity
Targeted delivery platforms are being used to reprogram the tumor microenvironment while concentrating immunotherapy at the tumor site. Lipid nanoparticles, nanoemulsions, EV-liposome hybrids and engineered bacteria deliver drugs, siRNA or checkpoint-inhibiting nanobodies. Adenosine signaling, lipid metabolism and age-associated myeloid inflammation recur as suppressive circuits to disrupt. The work is predominantly preclinical, with delivery precision and clinical feasibility still unresolved.
6 papers · 30%
Anti-PD-L1 serves as a tumor-retention anchor for sequential nanoparticle delivery
The supramolecular pretargeting lipid nanoparticles in cancer immunotherapy use ADA-conjugated anti-PD-L1 antibody not only to block the PD-1/PD-L1 checkpoint but also to prime tumors for host–guest capture of subsequently administered CB[7]-functionalized nanoparticles 42839730Oct. This makes anti-PD-L1 a spatial delivery scaffold that concentrates an independently engineered LNP cargo—NLG919 and IL-2-Fc–encoding circular RNA—at the tumor, adding a targeting and retention function beyond direct immune checkpoint blockade.
Papers
The 20 papers from the last 6 months that study Anti-PD-L1 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Metabolic Tumor Immunotherapy (7)
- Differential peripheral immune dynamics underlie therapeutic response to chemotherapy and chemoimmunotherapy in triple-negative breast cancer. ImmunoHorizons · 22 Sept 2026 PMID 42772938
- Engineered probiotics for tumor-targeted combination chemoimmunotherapy. Science translational medicine · 16 Sept 2026 PMID 42748218
- Integrin α2 (CD49b) blockade remodels the tumor immune microenvironment and enhances anti-PD-L1 therapy in 4T1 breast cancer model. Breast cancer research and treatment · 16 Sept 2026 PMID 42747603
- Low-Density Lipoprotein-Mimetic Nanoparticles Codelivering Self-Activated Cabazitaxel Prodrug and Verteporfin for Tumor Chemophotodynamic Therapy and Immune Activation. Molecular pharmaceutics · 7 Sept 2026 PMID 42704120
- Gemcitabine enhanced the sensitivity of colorectal cancer to anti-PD-L1 therapy by promoting lactylation. International immunopharmacology · 20 Jun 2026 PMID 42322856
- rSiglec-10(V set) armed oncolytic adenovirus improves the effects of virotherapy through enhancing oncolysis and antitumor immunity. International immunopharmacology · 18 Jun 2026 PMID 42314554
- Engineering Hypoxia-Lactate-Ca Coupling for Metabolic-Ion Intervention in Cancer Immunotherapy. ACS applied materials & interfaces · 10 Jun 2026 PMID 42268380
PD-L1 Resistance and Targeting (7)
- The deubiquitinase USP5 mediates anti-PD-L1 resistance in breast cancer by stabilizing FOXM1 to upregulate Nectin2. Human cell · 22 Sept 2026 PMID 42771124
- Intratumoral Bacillus cereus orchestrates stem-like lymphoid niches to potentiate immunotherapy response in hepatocellular carcinoma. Cancer cell · 17 Aug 2026 PMID 42607676
- Deciphering the immune landscape of parathyroid carcinoma: implications for immunotherapeutic responsiveness. Endocrine · 8 Aug 2026 PMID 42570161
- Repurposed ethoxzolamide reprograms antitumor immunity through β-TrCP-dependent PD-L1 ubiquitination. Cell reports. Medicine · 13 Jul 2026 PMID 42442361
- Novel Selenium-Containing Small Molecule PD-L1 Inhibitors: Design, Synthesis, and Evaluation of the Antitumor Activity. Journal of medicinal chemistry · 3 Jul 2026 PMID 42394434
- Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell · 22 Jun 2026 PMID 42330950
- Engineering and characterization of a novel PD-L1/VEGF bispecific antibody with enhanced VEGF-neutralizing capacity. Biochemical and biophysical research communications · 10 Jun 2026 PMID 42269274
Nanomedicine for Tumor Immunity (6)
- BBR-RHE Co-Loaded Nanoemulsion Potentiates Anti-PD-L1 Efficacy via Lipid Metabolic Reprogramming in Triple-Negative Breast Cancer. Molecular pharmaceutics · 2 Nov 2026 PMID 42969725
- Single-Particle Deconvolution of Electroporation Artifacts Guides the Rational Engineering of CD47-EV-Liposome Hybrids for siRNA Delivery. ACS applied materials & interfaces · 14 Oct 2026 PMID 42873218
- Supramolecular Pretargeting Lipid Nanoparticles Based on Host-Guest Recognition Potentiate Cancer Immunotherapy by Reprogramming Tumor Microenvironment. Angewandte Chemie (International ed. in English) · 7 Oct 2026 PMID 42839730
- Engineering Nonpathogenic Bacteria for Synergistic Tumor-Targeted Protein Degradation and Immunotherapy by Checkpoint-Inhibiting Nanobodies. Journal of the American Chemical Society · 20 Aug 2026 PMID 42619138
- Chelerythrine and chelidonine synergistically target the adenosine pathway to improve anti-PD-L1 immunotherapy efficacy in lung cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology · 17 Aug 2026 PMID 42607553
- Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy. Nature communications · 21 Jul 2026 PMID 42481458
By study type
Human data, design not indexed (2)
- Differential peripheral immune dynamics underlie therapeutic response to chemotherapy and chemoimmunotherapy in triple-negative breast cancer. ImmunoHorizons · 22 Sept 2026 PMID 42772938
- Deciphering the immune landscape of parathyroid carcinoma: implications for immunotherapeutic responsiveness. Endocrine · 8 Aug 2026 PMID 42570161
Preclinical: animal, cell and lab studies (16)
- BBR-RHE Co-Loaded Nanoemulsion Potentiates Anti-PD-L1 Efficacy via Lipid Metabolic Reprogramming in Triple-Negative Breast Cancer. Molecular pharmaceutics · 2 Nov 2026 PMID 42969725
- Single-Particle Deconvolution of Electroporation Artifacts Guides the Rational Engineering of CD47-EV-Liposome Hybrids for siRNA Delivery. ACS applied materials & interfaces · 14 Oct 2026 PMID 42873218
- The deubiquitinase USP5 mediates anti-PD-L1 resistance in breast cancer by stabilizing FOXM1 to upregulate Nectin2. Human cell · 22 Sept 2026 PMID 42771124
- Engineered probiotics for tumor-targeted combination chemoimmunotherapy. Science translational medicine · 16 Sept 2026 PMID 42748218
- Integrin α2 (CD49b) blockade remodels the tumor immune microenvironment and enhances anti-PD-L1 therapy in 4T1 breast cancer model. Breast cancer research and treatment · 16 Sept 2026 PMID 42747603
- Low-Density Lipoprotein-Mimetic Nanoparticles Codelivering Self-Activated Cabazitaxel Prodrug and Verteporfin for Tumor Chemophotodynamic Therapy and Immune Activation. Molecular pharmaceutics · 7 Sept 2026 PMID 42704120
- Engineering Nonpathogenic Bacteria for Synergistic Tumor-Targeted Protein Degradation and Immunotherapy by Checkpoint-Inhibiting Nanobodies. Journal of the American Chemical Society · 20 Aug 2026 PMID 42619138
- Chelerythrine and chelidonine synergistically target the adenosine pathway to improve anti-PD-L1 immunotherapy efficacy in lung cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology · 17 Aug 2026 PMID 42607553
- Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy. Nature communications · 21 Jul 2026 PMID 42481458
- Repurposed ethoxzolamide reprograms antitumor immunity through β-TrCP-dependent PD-L1 ubiquitination. Cell reports. Medicine · 13 Jul 2026 PMID 42442361
- Novel Selenium-Containing Small Molecule PD-L1 Inhibitors: Design, Synthesis, and Evaluation of the Antitumor Activity. Journal of medicinal chemistry · 3 Jul 2026 PMID 42394434
- Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell · 22 Jun 2026 PMID 42330950
- Gemcitabine enhanced the sensitivity of colorectal cancer to anti-PD-L1 therapy by promoting lactylation. International immunopharmacology · 20 Jun 2026 PMID 42322856
- rSiglec-10(V set) armed oncolytic adenovirus improves the effects of virotherapy through enhancing oncolysis and antitumor immunity. International immunopharmacology · 18 Jun 2026 PMID 42314554
- Engineering and characterization of a novel PD-L1/VEGF bispecific antibody with enhanced VEGF-neutralizing capacity. Biochemical and biophysical research communications · 10 Jun 2026 PMID 42269274
- Engineering Hypoxia-Lactate-Ca Coupling for Metabolic-Ion Intervention in Cancer Immunotherapy. ACS applied materials & interfaces · 10 Jun 2026 PMID 42268380
Unclassified: not yet indexed with MeSH (2)
- Supramolecular Pretargeting Lipid Nanoparticles Based on Host-Guest Recognition Potentiate Cancer Immunotherapy by Reprogramming Tumor Microenvironment. Angewandte Chemie (International ed. in English) · 7 Oct 2026 PMID 42839730
- Intratumoral Bacillus cereus orchestrates stem-like lymphoid niches to potentiate immunotherapy response in hepatocellular carcinoma. Cancer cell · 17 Aug 2026 PMID 42607676
Written from 20 PubMed abstracts, each one listed by PMID above. Published: 2026-06-17. Last written: 2026-09-24 by GPT. Drafted by language models from published abstracts; not medical advice.